16:50 , Oct 17, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Glaucoma Mouse studies suggest activating Tie2 could help treat primary open-angle glaucoma (POAG). In a mouse model of POAG, intraocular injection of a Tie2-activating antibody decreased intraocular pressure compared with a control antibody. Next...
06:13 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

Aerpio begins Phase IIb of AKB-9778 in diabetic retinopathy

Aerpio Pharmaceuticals Inc. (Cincinnati, Ohio) began the Phase IIb TIME-2b trial to evaluate once- and twice-daily 15 mg subcutaneous AKB-9778 for 12 months in about 150 patients with moderate to severe non-proliferative diabetic retinopathy. The...
22:31 , Mar 16, 2017 |  BC Extra  |  Financial News

Aerpio raises $40M ahead of planned OTC listing

Aerpio Pharmaceuticals Inc. (Cincinnati, Ohio) raised $40 million in a private placement and completed a reverse merger. President and CEO Joseph Gardner told BioCentury the transactions are part of a stepwise process in which the...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

AKB-9778: Additional Phase IIa data

Additional data from the double-blind, U.S. Phase IIa TIME-2 trial in 144 patients with DME showed that twice-daily 15 mg subcutaneous AKB-9778 with and without once-monthly Lucentis ranibizumab led to a >=2-step improvement on the...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

AKB-9778: Phase IIa data

Top-line data from the double-blind, U.S. Phase IIa TIME-2 trial in 144 patients showed that twice-daily 15 mg subcutaneous AKB-9778 plus once-monthly Lucentis ranibizumab significantly reduced CST from baseline to 3 months, the primary endpoint,...
01:19 , Jul 16, 2015 |  BC Extra  |  Clinical News

Aerpio combo tops Lucentis alone in DME study

Aerpio Therapeutics Inc. (Cincinnati, Ohio) said a combination of its AKB-9778 and Lucentis ranibizumab was superior to Lucentis alone in the Phase IIa TIME-2 study to treat diabetic macular edema (DME). The combination met the...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Clinical News

AKB-9778: Additional Phase Ib/IIa data

Additional data from the open-label, dose-escalation, U.S. Phase Ib/IIa TIME-1 trial in 18 evaluable patients with DME showed that twice-daily subcutaneous AKB-9778 at doses of >=15 mg for 28 days improved BCVA by >=5 letters...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Clinical News

AKB-9778: Completed Phase II enrollment

Aerpio completed enrollment of 144 patients in the double-blind, placebo-controlled, U.S. Phase II TIME-2 trial comparing 15 mg subcutaneous AKB-9778 twice daily with and without monthly Lucentis ranibizumab for 3 months vs. Lucentis alone. Aerpio...
07:00 , Apr 28, 2014 |  BioCentury  |  Finance

Venture hots up

Private biotechs have raised $3.1 billion since the start of the year, double the $1.5 billion raised in the same period last year. At least one investor contacted by BioCentury expects the pace to continue...
00:33 , Apr 24, 2014 |  BC Extra  |  Financial News

Aerpio raises $18 million in A-2 round

Aerpio Therapeutics Inc. (Cincinnati, Ohio) raised $18 million in a series A-2 round led by new investor OrbiMed. Existing investors Novartis Venture Funds; Satter Investment Management; Kearny Venture Partners; Venture Investors; Triathlon Medical Ventures; and...